U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C2H3O2.Na.3H2O
Molecular Weight 136.0796
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SODIUM ACETATE

SMILES

O.O.O.[Na+].CC([O-])=O

InChI

InChIKey=AYRVGWHSXIMRAB-UHFFFAOYSA-M
InChI=1S/C2H4O2.Na.3H2O/c1-2(3)4;;;;/h1H3,(H,3,4);;3*1H2/q;+1;;;/p-1

HIDE SMILES / InChI

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C2H4O2
Molecular Weight 60.052
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Hydroxocobalamin (also hydroxycobalamin, OHCbl) is a natural form, or vitamer, of vitamin B12. It is a member of the cobalamin family of compounds. Hydroxocobalamin, the active ingredient in Cyanokit, is cobinamide dihydroxide dihydrogen phosphate (ester), mono (inner salt), 3’-ester with 5,6-dimethyl-1-α-D-ribofuranosyl-1H-benzimidazole. The drug substance is the hydroxylated active form of vitamin B12 and is a large molecule in which a trivalent cobalt ion is coordinated in four positions by a tetrapyrol (or corrin) ring. It is a hygroscopic, odorless, dark red, crystalline powder that is freely soluble in water and ethanol, and practically insoluble in acetone and diethyl ether. Cyanokit contains hydroxocobalamin, an antidote indicated for the treatment of known or suspected cyanide poisoning. Cyanide is an extremely toxic poison. In the absence of rapid and adequate treatment, exposure to a high dose of cyanide can result in death within minutes due to the inhibition of cytochrome oxidase resulting in arrest of cellular respiration. Specifically, cyanide binds rapidly with cytochrome a3, a component of the cytochrome c oxidase complex in mitochondria. Inhibition of cytochrome a3 prevents the cell from using oxygen and forces anaerobic metabolism, resulting in lactate production, cellular hypoxia and metabolic acidosis. In massive acute cyanide poisoning, the mechanism of toxicity may involve other enzyme systems as well. Signs and symptoms of acute systemic cyanide poisoning may develop rapidly within minutes, depending on the route and extent of cyanide exposure. The action of Cyanokit is based on its ability to bind cyanide ions. Each hydroxocobalamin molecule can bind one cyanide ion by substituting it for the hydroxo ligand linked to the trivalent cobalt ion, to form cyanocobalamin, which is then excreted in the urine.

CNS Activity

Curator's Comment: Acetic acid was shown to cross the blood brain barrier in rats.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
CYANOKIT

Approved Use

Cyanokit contains hydroxocobalamin, an antidote indicated for the treatment of known or suspected cyanide poisoning. (1.1) If clinical suspicion of cyanide poisoning is high, Cyanokit should be administered without delay. (1.2) The expert advice of a regional poison control center may be obtained by calling 1-800-222-1222. (1.2) 1.1 Indication Cyanokit is indicated for the treatment of known or suspected cyanide poisoning. 1.2 Identifying Patients with Cyanide Poisoning Cyanide poisoning may result from inhalation, ingestion, or dermal exposure to various cyanide-containing compounds, including smoke from closed-space fires. Sources of cyanide poisoning include hydrogen cyanide and its salts, cyanogenic plants, aliphatic nitriles, and prolonged exposure to sodium nitroprusside. The presence and extent of cyanide poisoning are often initially unknown. There is no widely available, rapid, confirmatory cyanide blood test. Treatment decisions must be made on the basis of clinical history and signs and symptoms of cyanide intoxication. If clinical suspicion of cyanide poisoning is high, Cyanokit should be administered without delay. Table 1 Common Signs and Symptoms of Cyanide Poisoning Symptoms Signs Headache Altered Mental Status (e.g., confusion,disorientation) Confusion Seizures or Coma Dyspnea Mydriasis Chest tightness Tachypnea / Hyperpnea (early) Nausea Bradypnea / Apnea (late) Hypertension (early) / Hypotension (late) Cardiovascular collapse Vomiting Plasma lactate concentration ≥ 8 mmol/L In some settings, panic symptoms including tachypnea and vomiting may mimic early cyanide poisoning signs. The presence of altered mental status (e.g., confusion and disorientation) and/or mydriasis is suggestive of true cyanide poisoning although these signs can occur with other toxic exposures as well. The expert advice of a regional poison control center may be obtained by calling 1-800-222-1222. Smoke Inhalation Not all smoke inhalation victims will have cyanide poisoning and may present with burns, trauma, and exposure to other toxic substances making a diagnosis of cyanide poisoning particularly difficult. Prior to administration of Cyanokit, smoke-inhalation victims should be assessed for the following: Exposure to fire or smoke in an enclosed area Presence of soot around the mouth, nose or oropharynx Altered mental status Although hypotension is highly suggestive of cyanide poisoning, it is only present in a small percentage of cyanide-poisoned smoke inhalation victims. Also indicative of cyanide poisoning is a plasma lactate concentration ≥ 10 mmol/L (a value higher than that typically listed in the table of signs and symptoms of isolated cyanide poisoning because carbon monoxide associated with smoke inhalation also contributes to lactic acidemia). If cyanide poisoning is suspected, treatment should not be delayed to obtain a plasma lactate concentration. 1.3 Use with Other Cyanide Antidotes Caution should be exercised when administering other cyanide antidotes simultaneously with Cyanokit, as the safety of co-administration has not been established. If a decision is made to administer another cyanide antidote with Cyanokit, these drugs should not be administered concurrently in the same intravenous line. [see Dosage and Administration (2.3)

Launch Date

2006
Curative
VOSOL

Approved Use

For the treatment of superficial infections of the external auditory canal caused by organisms susceptible to the action of the antimicrobial.

Launch Date

1960
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4511.6 μM × h
5 g single, intravenous
dose: 5 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
HYDROXOCOBALAMIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
26.2 h
5 g single, intravenous
dose: 5 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
HYDROXOCOBALAMIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
20 mg 1 times / day multiple, intramuscular
Dose: 20 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, 13 years
n = 1
Health Status: unhealthy
Age Group: 13 years
Sex: M
Population Size: 1
Sources:
20 g single, intravenous
Highest studied dose
Dose: 20 g
Route: intravenous
Route: single
Dose: 20 g
Sources:
unhealthy, 26.9 years
n = 1
Health Status: unhealthy
Age Group: 26.9 years
Sex: M
Population Size: 1
Sources:
5 g single, intravenous
Overdose
Dose: 5 g
Route: intravenous
Route: single
Dose: 5 g
Sources:
unhealthy, 3 years
n = 1
Health Status: unhealthy
Condition: cyanide toxicity
Age Group: 3 years
Sex: F
Population Size: 1
Sources:
5 g single, intravenous
Dose: 5 g
Route: intravenous
Route: single
Dose: 5 g
Sources:
unhealthy, 62 years
n = 1
Health Status: unhealthy
Condition: Vasoplegic Syndrome
Age Group: 62 years
Sex: M
Population Size: 1
Sources:
2000 ug 2 times / day multiple, oral
Dose: 2000 ug, 2 times / day
Route: oral
Route: multiple
Dose: 2000 ug, 2 times / day
Sources:
unhealthy, adult
n = 8
Health Status: unhealthy
Condition: pernicious anaemia
Age Group: adult
Population Size: 8
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​Drug as victim

Drug as victim

Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Evaluation of copper availability to plants in copper-contaminated vineyard soils.
2001
Brain dystrophin-glycoprotein complex: persistent expression of beta-dystroglycan, impaired oligomerization of Dp71 and up-regulation of utrophins in animal models of muscular dystrophy.
2001
Exploring infection of wheat and carbohydrate metabolism in Mycosphaerella graminicola transformants with differentially regulated green fluorescent protein expression.
2001 Feb
In vivo (13)C NMR measurement of neurotransmitter glutamate cycling, anaplerosis and TCA cycle flux in rat brain during.
2001 Feb
Analgesic and anti-inflammatory effects of Mangifera indica L. extract (Vimang).
2001 Feb
Metabolic shifts and myocyte hypertrophy in deflazacort treatment of mdx mouse cardiomyopathy.
2001 Feb
In silico predictions of Escherichia coli metabolic capabilities are consistent with experimental data.
2001 Feb
Structure of manganese diacetate tetrahydrate and low-temperature methyl-group dynamics.
2001 Feb
Pharmacodynamic effects and plasma pharmacokinetics of single doses of cetrorelix acetate in healthy premenopausal women.
2001 Feb
Lipase-catalyzed irreversible transesterification of 1-(2-furyl)ethanol using isopropenyl acetate.
2001 Feb
Development of xylose-fermenting yeast Pichia stipitis for ethanol production through adaptation on hardwood hemicellulose acid prehydrolysate.
2001 Feb
DNA-protein crosslinks induced by nickel compounds in isolated rat lymphocytes: role of reactive oxygen species and specific amino acids.
2001 Feb 1
Physiological responses to mixing in large scale bioreactors.
2001 Feb 13
Arginine catabolism by Thermanaerovibrio acidaminovorans.
2001 Feb 20
Clostridium hungatei sp. nov., a mesophilic, N2-fixing cellulolytic bacterium isolated from soil.
2001 Jan
In vitro mixed ruminal microorganism fermentation of whole cottonseed coated with gelatinized corn starch and urea.
2001 Jan
Effect of ruminal vs postruminal administration of degradable protein on utilization of low-quality forage by beef steers.
2001 Jan
Determination of cilostazol and its metabolites in human urine by high performance liquid chromatography.
2001 Jan
Measurement of myocardial blood flow with PET using 1-11C-acetate.
2001 Jan
Expression of alpha-amylase gene in rat liver: liver-specific amylase has a high affinity to glycogen.
2001 Jan
Acetylcholinesterase assay for rapid expression screening in liquid and solid media.
2001 Jan
Immunobiology of the reproductive tract in a female baboon.
2001 Jan
Insecticidal activity of common reagents for insect foreign bodies of the ear.
2001 Jan
Physical stability of the blue pigments formed from geniposide of gardenia fruits: effects of pH, temperature, and light.
2001 Jan
N(delta)-(5-hydroxy-4,6-dimethylpyrimidine-2-yl)-l-ornithine, a novel methylglyoxal-arginine modification in beer.
2001 Jan
The metal binding properties of the CCCH motif of the 50S ribosomal protein L36 from Thermus thermophilus.
2001 Jan
New analogues of bradykinin containing a conformationally restricted dipeptide fragment in their molecules.
2001 Jan
Purification and characterization of a cellulase from the ruminal fungus Orpinomyces joyonii cloned in Escherichia coli.
2001 Jan
Peripheral and preemptive opioid antinociception in a mouse visceral pain model.
2001 Jan
Comparison of myocardial oxygen consumption using 11C acetate positron emission tomography scanning in a working and non-working heart transplant model.
2001 Jan
Novel test and its automation for the determination of erythrocyte acetylcholinesterase and its application to organophosphate exposure.
2001 Jan
Precursor supply for polyketide biosynthesis: the role of crotonyl-CoA reductase.
2001 Jan
Preparations, characterizations, and structures of (biimidazole)dihalobis(triphenylphosphine)rhenium(III) salts: strong ion-pairing and acid-base properties.
2001 Jan 1
Control of electrochemical reactions at the capillary electrophoresis outlet/electrospray emitter electrode under CE/ESI-MS through the application of redox buffers.
2001 Jan 15
Inactivation of infective larvae of Angiostrongylus costaricensis with short time incubations in 1.5% bleach solution, vinegar or saturated cooking salt solution.
2001 Jan 15
Modelling the influence of pH and organic acid types on thermal inactivation of Bacillus cereus spores.
2001 Jan 22
Identification of lactic acid bacteria constituting the predominating microflora in an acid-fermented condiment (tempoyak) popular in Malaysia.
2001 Jan 22
Acetate as a carbon source for hydrogen production by photosynthetic bacteria.
2001 Jan 23
Di-tert-butyl phosphate complexes of cobalt(II) and zinc(II) as precursors for ceramic M(PO3)2 and M2P2O7 materials: synthesis, spectral characterization, structural studies, and role of auxiliary ligands.
2001 Jan 29
[DOTA-bis(amide)]lanthanide complexes: NMR evidence for differences in water-molecule exchange rates for coordination isomers.
2001 Jan 5
Optimised determination of clobazam in human plasma with extraction and high-performance liquid chromatography analysis.
2001 Jan 5
[Acetyl starch as volume substitute, a possible alternative to HES].
2001 Jan 5
Evaluation of a novel vitamin E coated cellulosic membrane hollow fiber dialyzer.
2001 Jan-Feb
Metabolic fate of [14C]-ethanol into endothelial cell phospholipids including platelet-activating factor, sphingomyelin and phosphatidylethanol.
2001 Jan-Feb
S-methyl-N,N-diethylthiocarbamate sulfoxide elicits neuroprotective effect against N-methyl-D-aspartate receptor-mediated neurotoxicity.
2001 Jan-Feb
Salt accumulation resulting from base added for pH control, and not ethanol, limits growth of Thermoanaerobacteriumthermosaccharolyticum HG-8 at elevated feed xylose concentrations in continuous culture.
2001 Jan-Feb
Conversion of sugars to 1,2-propanediol by Thermoanaerobacterium thermosaccharolyticum HG-8.
2001 Jan-Feb
Production of ethanol and xylitol from corn cobs by yeasts.
2001 Mar
Acute and chronic toxicity of Potassium Chloride (KCl) and Potassium Acetate (KC(2)H(3)O(2)) to Daphnia similis and Ceriodaphnia dubia (Crustacea; Cladocera).
2001 Mar
Measurement of low picomolar levels of triamcinolone acetonide in human bronchoalveolar lavage fluid by gas chromatography-electron-capture negative-ion mass spectrometry.
2001 Mar 1
Patents

Sample Use Guides

To promote continuous contact, insert a wick of cotton saturated with the drug solution (Vosol). Keep the wick in for at least 24 hours and keep it moist by adding 3 to 5 drops of solution every 4 to 6 hours. The wick may be removed after 24 hours but the patient should continue to instill 5 drops of the drug solution 3 or 4 times daily thereafter, for as long as indicated.
Route of Administration: Otic (auricular)
In Vitro Use Guide
Curator's Comment: Hydroxocobalamin (OH-Cbl), when used to treat vitamin B12 deficiency, is better retained by the body than is cyanocobalamin (CN-Cbl), but the availability to cells has not been studied systematically. In a series of experiments, were compared the uptake and internalization of OH-Cbl and CN-Cbl bound to transcobalamin II (TCII) by a human cell model, the HeLa cell. TCII-OH-Cbl was: (1) taken up in larger amounts per unit time, (2) the greater uptake was not a consequence of more effective attachment to receptors of TCII-Cbl nor to a more rapid regeneration of receptors, (3) the difference was expressed during the phase of internalization of TCII-Cbl, (4) with CN-Cbl, the stages of binding to receptors plus internalization were more readily reversed, and (5) larger amounts of OH-Cbl were internalized and converted to active coenzyme forms of Cbl.
Acetic acid inhibited Saccharomyces cerevisiae growth. The minimum inhibitory concentration (MIC) of acetic acid for yeast growth was 0.6% w/v (100 mM).
Substance Class Chemical
Created
by admin
on Sat Dec 16 20:13:46 GMT 2023
Edited
by admin
on Sat Dec 16 20:13:46 GMT 2023
Record UNII
4550K0SC9B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SODIUM ACETATE
FCC   II   INCI   ORANGE BOOK   USP   VANDF  
INCI  
Official Name English
E-262(I)
Code English
SODIUM ACETATE [USP MONOGRAPH]
Common Name English
SODIUM ACETATE [INCI]
Common Name English
SODIUM ACETATE [FCC]
Common Name English
SODIUM ACETATE [VANDF]
Common Name English
ACETIC ACID, SODIUM SALT, HYDRATE (1:1:3)
Common Name English
Sodium acetate trihydrate
EP   MI   USP-RS   WHO-DD  
Systematic Name English
SODIUM ACETATE HYDRATE
JAN  
Systematic Name English
ACETIC ACID, SODIUM SALT, TRIHYDRATE
Common Name English
SODIUM ACETATE [USP-RS]
Common Name English
INS NO.262(I)
Code English
SODIUM ACETATE TRIHYDRATE [MI]
Common Name English
SODIUM ACETATE HYDRATE [JAN]
Common Name English
Sodium acetate trihydrate [WHO-DD]
Common Name English
SODIUM ACETATE [II]
Common Name English
SODIUM ACETATE TRIHYDRATE [USP-RS]
Common Name English
INS-262(I)
Code English
SODIUM ACETATE (3H2O)
Common Name English
SODIUM ACETATE [ORANGE BOOK]
Common Name English
SODIUM ACETATE TRIHYDRATE [EP MONOGRAPH]
Common Name English
Classification Tree Code System Code
JECFA EVALUATION INS-262(I)
Created by admin on Sat Dec 16 20:13:47 GMT 2023 , Edited by admin on Sat Dec 16 20:13:47 GMT 2023
EPA PESTICIDE CODE 44006
Created by admin on Sat Dec 16 20:13:47 GMT 2023 , Edited by admin on Sat Dec 16 20:13:47 GMT 2023
WHO-VATC QB05XA08
Created by admin on Sat Dec 16 20:13:47 GMT 2023 , Edited by admin on Sat Dec 16 20:13:47 GMT 2023
CFR 21 CFR 184.1721
Created by admin on Sat Dec 16 20:13:46 GMT 2023 , Edited by admin on Sat Dec 16 20:13:46 GMT 2023
CODEX ALIMENTARIUS (GSFA) INS-262(I)
Created by admin on Sat Dec 16 20:13:46 GMT 2023 , Edited by admin on Sat Dec 16 20:13:46 GMT 2023
WHO-ATC B05XA08
Created by admin on Sat Dec 16 20:13:46 GMT 2023 , Edited by admin on Sat Dec 16 20:13:46 GMT 2023
NCI_THESAURUS C29730
Created by admin on Sat Dec 16 20:13:47 GMT 2023 , Edited by admin on Sat Dec 16 20:13:47 GMT 2023
Code System Code Type Description
WIKIPEDIA
SODIUM ACETATE
Created by admin on Sat Dec 16 20:13:47 GMT 2023 , Edited by admin on Sat Dec 16 20:13:47 GMT 2023
PRIMARY
MERCK INDEX
m9979
Created by admin on Sat Dec 16 20:13:47 GMT 2023 , Edited by admin on Sat Dec 16 20:13:47 GMT 2023
PRIMARY Merck Index
FDA UNII
4550K0SC9B
Created by admin on Sat Dec 16 20:13:47 GMT 2023 , Edited by admin on Sat Dec 16 20:13:47 GMT 2023
PRIMARY
PUBCHEM
23665404
Created by admin on Sat Dec 16 20:13:47 GMT 2023 , Edited by admin on Sat Dec 16 20:13:47 GMT 2023
PRIMARY
EVMPD
SUB15266MIG
Created by admin on Sat Dec 16 20:13:46 GMT 2023 , Edited by admin on Sat Dec 16 20:13:46 GMT 2023
PRIMARY
DRUG BANK
DB09395
Created by admin on Sat Dec 16 20:13:46 GMT 2023 , Edited by admin on Sat Dec 16 20:13:46 GMT 2023
PRIMARY
CAS
6131-90-4
Created by admin on Sat Dec 16 20:13:46 GMT 2023 , Edited by admin on Sat Dec 16 20:13:46 GMT 2023
PRIMARY
EVMPD
SUB12576MIG
Created by admin on Sat Dec 16 20:13:46 GMT 2023 , Edited by admin on Sat Dec 16 20:13:46 GMT 2023
PRIMARY
DAILYMED
4550K0SC9B
Created by admin on Sat Dec 16 20:13:46 GMT 2023 , Edited by admin on Sat Dec 16 20:13:46 GMT 2023
PRIMARY
CHEBI
32954
Created by admin on Sat Dec 16 20:13:46 GMT 2023 , Edited by admin on Sat Dec 16 20:13:46 GMT 2023
PRIMARY
NCI_THESAURUS
C47720
Created by admin on Sat Dec 16 20:13:47 GMT 2023 , Edited by admin on Sat Dec 16 20:13:47 GMT 2023
PRIMARY
DRUG CENTRAL
4203
Created by admin on Sat Dec 16 20:13:47 GMT 2023 , Edited by admin on Sat Dec 16 20:13:47 GMT 2023
PRIMARY
ChEMBL
CHEMBL1354
Created by admin on Sat Dec 16 20:13:46 GMT 2023 , Edited by admin on Sat Dec 16 20:13:46 GMT 2023
PRIMARY
EPA CompTox
DTXSID2073986
Created by admin on Sat Dec 16 20:13:47 GMT 2023 , Edited by admin on Sat Dec 16 20:13:47 GMT 2023
PRIMARY
SMS_ID
100000089838
Created by admin on Sat Dec 16 20:13:47 GMT 2023 , Edited by admin on Sat Dec 16 20:13:47 GMT 2023
PRIMARY
RS_ITEM_NUM
1613429
Created by admin on Sat Dec 16 20:13:47 GMT 2023 , Edited by admin on Sat Dec 16 20:13:47 GMT 2023
PRIMARY
RXCUI
56443
Created by admin on Sat Dec 16 20:13:47 GMT 2023 , Edited by admin on Sat Dec 16 20:13:47 GMT 2023
ALTERNATIVE
RXCUI
237108
Created by admin on Sat Dec 16 20:13:47 GMT 2023 , Edited by admin on Sat Dec 16 20:13:47 GMT 2023
PRIMARY
MESH
D019346
Created by admin on Sat Dec 16 20:13:47 GMT 2023 , Edited by admin on Sat Dec 16 20:13:47 GMT 2023
PRIMARY
CHEBI
32138
Created by admin on Sat Dec 16 20:13:46 GMT 2023 , Edited by admin on Sat Dec 16 20:13:46 GMT 2023
PRIMARY
Related Record Type Details
ANHYDROUS->SOLVATE
Related Record Type Details
ACTIVE MOIETY
ACTIVE MOIETY